| 23rd Sep 2024 7:05 am |
RNS |
Fasenra recommended for EU approval in EGPA |
| 23rd Sep 2024 7:00 am |
RNS |
Final OS results reported for TROPION-Breast01 |
| 20th Sep 2024 6:00 pm |
RNS |
FluMist approved for self-administration in US |
| 18th Sep 2024 7:00 am |
RNS |
Fasenra EGPA US FDA approval |
| 13th Sep 2024 3:15 pm |
RNS |
Director/PDMR Shareholding |
| 2nd Sep 2024 3:00 pm |
RNS |
Total Voting Rights |
| 16th Aug 2024 7:00 am |
RNS |
Imfinzi approved in US for resectable lung cancer |
| 1st Aug 2024 3:00 pm |
RNS |
Total Voting Rights |
| 30th Jul 2024 7:00 am |
RNS |
AstraZeneca prices a €1.4bn bond offering |
| 29th Jul 2024 8:41 am |
RNS |
Stabilisation Notice - ASTRAZENECA |
| 29th Jul 2024 7:00 am |
RNS |
Calquence fixed-duration combo improved 1L CLL PFS |
| 26th Jul 2024 7:00 am |
RNS |
ODAC reviewed Imfinzi in resectable lung cancer |
| 25th Jul 2024 7:00 am |
RNS |
Half-year Report |
| 15th Jul 2024 7:00 am |
RNS |
Acquisition of Amolyt Pharma completed |
| 1st Jul 2024 3:00 pm |
RNS |
Total Voting Rights |
| 1st Jul 2024 7:00 am |
RNS |
Lynparza & Imfinzi positive CHMP in endometrial |
| 25th Jun 2024 7:05 am |
RNS |
Update on Imfinzi ADJUVANT BR.31 trial |
| 25th Jun 2024 7:00 am |
RNS |
Imfinzi improved EFS and OS in bladder cancer |
| 18th Jun 2024 7:00 am |
RNS |
Update on CAPItello-290 Phase III trial |
| 17th Jun 2024 7:00 am |
RNS |
Imfinzi approved in the US for endometrial cancer |
| 12th Jun 2024 3:00 pm |
RNS |
Director/PDMR Shareholding |
| 5th Jun 2024 7:00 am |
RNS |
Acquisition of Fusion completed |
| 3rd Jun 2024 3:05 pm |
RNS |
Block listing Interim Review |
| 3rd Jun 2024 3:00 pm |
RNS |
Total Voting Rights |
| 3rd Jun 2024 7:00 am |
RNS |
Tagrisso plus chemo recommended for approval in EU |
| 28th May 2024 7:00 am |
RNS |
Dato-DXd improved OS in nonsquamous lung cancer |
| 21st May 2024 7:00 am |
RNS |
AstraZeneca to deliver $80bn revenue by 2030 |
| 20th May 2024 7:00 am |
RNS |
AstraZeneca to manufacture ADCs in Singapore |
| 16th May 2024 7:00 am |
RNS |
SUPERNOVA Trial Met COVID-19 prevention endpoint |
| 15th May 2024 3:00 pm |
RNS |
Director/PDMR Shareholding |
| 7th May 2024 7:00 am |
RNS |
AstraZeneca completes Cellectis equity investment |
| 2nd May 2024 7:00 am |
RNS |
Calquence combination improved PFS in 1L MCL |
| 1st May 2024 3:00 pm |
RNS |
Total Voting Rights |
| 29th Apr 2024 7:05 am |
RNS |
Truqap recommended for EU breast cancer approval |
| 29th Apr 2024 7:00 am |
RNS |
Enhertu improved PFS in HER2-low and ultralow |
| 25th Apr 2024 7:00 am |
RNS |
1st Quarter Results |
| 11th Apr 2024 5:30 pm |
RNS |
Result of AGM |
| 11th Apr 2024 7:00 am |
RNS |
AstraZeneca increases 2024 dividend by 7% |
| 8th Apr 2024 7:00 am |
RNS |
Enhertu approved in US for HER2+ solid tumours |
| 5th Apr 2024 7:00 am |
RNS |
Imfinzi improved OS & PFS in limited-stage SCLC |
